RapiOmics-Plex: A Platform for Rapid Detection of Highly Multiplexed Multi-omics Biomarker Panel

Combat-related PTSD is closely linked to traumatic experiences during military service, including combat exposure, witnessing casualties, and experiencing life-threatening situations. This condition has a profound and lasting impact on many U.S. veterans and the broader U.S. population. Current diagnostic approaches for PTSD rely primarily on clinical interviews and psychological assessments, which can be time-consuming and subjective. Consequently, developing a molecular diagnostic tool to identify and treat individuals with PTSD accurately is crucial. Previous biomarker studies have primarily focused on gene expression to predict risk and diagnose PTSD, but these methods have shown limited clinical success. To achieve a more comprehensive understanding, recent investigations have emphasized the importance of multi-omic biomarkers for the early and precise identification of PTSD. These biomarkers enable accurate diagnosis, provide valuable prognostic information, and guide personalized treatment plans. The multi-omics approach encompasses genomics, transcriptomics, proteomics, and metabolomics analysis. However, detecting these multi-omic biomarkers requires multiple, complex technologies such as microarrays, diverse sequencing platforms, enzyme-linked immunosorbent assays (ELISA), and mass spectrometry. As a result, the current implementation of a multi-omic diagnostic system is costly, time-consuming, and impractical. Therefore, an urgent solution lies in developing an integrated in-vitro diagnostic tool that encompasses multiple -omics , specifically designed for CLIA environments. Recognizing this pressing need, CFD Research will leverage our expertise to develop a platform capable of quantifying multi-omic biomarkers from whole blood samples. This platform will be designed to meet the necessary parameters for a lab-developed test. We anticipate that this technology will fill the critical gap in detecting multi-omic biomarkers and may also find applications in other markets, such as broader PTSD diagnostics and cancer detection.